| Molecular Profiling of Spinal Disease Progression in Ankylosing Spondylitis |
Hwang |
NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases(NIAMS) |
| Phase I/II Study of AD-PluReceptor plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients with Autoimmune Disorders |
Assassi / Mayes |
UT MDACC through Donor Funds |
| Fibronere – A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) |
Mayes / Assassi |
Boehringer Ingelheim Pharmaceuticals |
| A 52-week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging, Study of Nemolizumab in Adult Subjects with Systemic Sclerosis |
Mayes / Assassi |
Galderma R&D Inc |
| Randomized, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Evaluate the Efficacy, Safety and Tolerability of Efzofitimod in Patients With Systemic Sclerosis Related Interstitial Lung Disease |
Mayes |
aTyr Pharma |
| A Double Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of PRA023 in Subjects with Systemic Sclerosis Associated with Interstitial Lung Disease (SSc-ILD) |
Mayes |
Prometheus Biosciences (now Merck) |
| A Multicenter, Randomized, Parallel-group, Double-blind, Two-arm, Phase III Study to Evaluate the Safety and Efficacy of Anifrolumab Compared with Placebo in Male and Female Participants 18 to 70 Years of Age Inclusive with Systemic Sclerosis |
Mayes |
AstraZeneca |
| A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2b Platform Clinical Trial Evaluating the Safety and Efficacy of Investigational Products in Patients with Interstitial Lung Disease Secondary to Systemic Sclerosis (CONQUEST) |
McMahan/ Mayes |
SRF/ Medpace Clinical Research |
| Fecal Microbiome Transplant (FMT) |
McMahan |
Donor Funded |
| Interrogating the pathophysiological mechanisms of constipation in patients with systemic sclerosis |
McMahan |
NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases(NIAMS) |
| RNA Polymerase III specific CD8+ T cells: a mechanistic insight into cancer-induced autoimmunity in scleroderma |
Tiniakou |
NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases(NIAMS) / Rheumatology Research Foundation |
| An Exploratory Clinical Trial of IVIG in anti-HMGCR ImmuneMediated Necrotizing Myopathy |
Tiniakou |
Univ of Alabama – Birmingham through NIH/NIAMSD & Industry Octopharma |
| Regulation of B cell Responses in SLE and Other Autoimmune Diseases |
Tiniakou |
Emory University / NIH/National Institute of Allergy & Infectious Disease |